Dotatate Supplies

Update on Lutathera

Following a recent audit sanctioned by the Department of Health and BNMS Council, a positive recommendation on Lutathera from the company AAA has been made. This document has been placed in a secure NHS website controlled by the NHS Pharmaceutical Quality Assurance committee.

NHS Clinicians and Radiopharmacies intending to purchase the product as an unlicensed pharmaceutical outside of the current clinical trial should contact either Paul Maltby (paul.maltby@rlbuht.nhs.uk) or Jilly Croasdale (j.croasdale@nhs.net) in the first instance for further information. It is expected that compliance with the requirements for unlicensed products as outlined in the QA of Radiopharmaceuticals document (http://www.bnms.org.uk/images/stories/UKRG/UKRG_QA_Apr-12.pdf) will form part of the purchase and use strategy for Lutathera.

 

EANM: Update on DOTATATE shortage, February 19, 2013

Dear Colleagues,
 
Please find hereafter a short résumé on the information that we have been able to collect from those of you who are directly involved in this crisis and from the companies producing or distributing peptides.
This document is intended only to be informative. Radiopharmaceuticals must be used according to national Law, EU Directives and EMA recommendations. Colleagues who are unable to continue Lu-177 DOTATATE treatments after in-house labeling due to the current DOTATATE-shortage are stimulated to call the EANM office at  +43 1 2 12 80 30.
Please contact us should you require any further clarification or wish to make suggestions. We shall keep you informed of any further developments.

Lutetium 177 Dotatate Supply

The BNMS has been made aware of a potential short-term difficulty in sourcing Lutetium 177 Dotatate for the treatment of neuroendocrine malignancy.